Search Results 2081-2090 of 19657 for hemoglobin

  1. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) - Mayo Clinic

    Hemoglobin ≥ 9 g/dL;; Absolute neutrophil count (ANC) ≥ 1.5 × 10^9 /L;; Creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft-Gault equation ...

  2. Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery - Mayo Clinic

    Hemoglobin (Hgb) ≥ 9 g/dL (within less than or equal to 14 days prior to randomization). Leukocytes ≥ 3,000/mm^3 (within less than or equal to 14 days ...

  3. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

    Hemoglobin ≥ 9 g/dL;; Absolute neutrophil count ≥ 1000/µL;; Platelet count ≥ 65000/µL;; Total bilirubin (TBL) ≤ 2.0 × upper limit of normal (ULN); ...

  4. A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

    * subjects in the venetoclax + JCAR017 combination must have hemoglobin \>=9 g/dL, absolute neutrophil count \>=500mm3 and platelets\>= 75,000/mm3, unless ...

  5. Hematology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  6. Neurosurgery - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  7. Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. - Mayo Clinic

    Hemoglobin ≥9 g/dL: transfusion to achieve this cutoff is not allowed within 14 days of first dose of study therapy; 3. Platelet count ≥100,000/mm3; 4 ...

  8. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 - Mayo Clinic

    - Hemoglobin ≥9 g/dL - Left ventricular ejection fraction (LVEF) ≥50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO). - It is ...

  9. Orthopedic Surgery - Clinical trials

    ... hemoglobin levels, 90-day complications, readmission and reoperation. A Study to Measure Elbow and Ankle Range-of-Motion via Teleconferencing. Jacksonville ...

  10. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL;; PT/INR, aPTT ≤ 1.5 x ULN unless participant is receiving a stable dose of therapeutic anticoagulation;; Albumin ≥ 3.0 g/dL ...